Cohance Lifesciences: USFDA inspects and classifies Telangana facility as ‘voluntary action indicated’


The US Food and Drug Administration (USFDA) has concluded inspecting Cohance Lifesciences Ltd’s formulation manufacturing facility in Shamshabad, Telangana, and it classified as Voluntary Action Indicated (VAI), the company said on November 21.

It was also issued an Establishment Inspection Report (EIR) for the facility.

VAI is an FDA classification indicating that regulatory action is not currently warranted, but the agency has identified issues that call for voluntary corrective action by the establishment. EIR, or Establishment Inspection Report, is the FDA’s formal report documenting the findings and outcome of an inspection.

The company had previously informed the exchanges about the USFDA inspection on September 5, 2026. “With the receipt of the EIR, the said inspection stands concluded,” Cohance Lifesciences said in a regulatory filing.

Shares of Cohance Lifesciences closed at ₹462.30 apiece on the NSE on Friday, November 20, up 0.62% for the day.

Home/Market News/

Cohance Lifesciences: USFDA inspects and classifies Telangana facility as ‘voluntary action indicated’



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *